October 20, 2016 5:43 PM ET


Company Overview of Sucampo Pharmaceuticals, Inc.

Executive Profile

Peter A. Kiener D.Phil.

Chief Science Officer, Sucampo Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 3 Board Members in 3 different organizations across 10 different industries.

See Board Relationships
As of Fiscal Year 2015


Dr. Peter A. Kiener, D.Phil. has been the Chief Science Officer at Sucampo Pharmaceuticals, Inc. since October 27, 2014. Dr. Kiener was a Co-Founder of Zyngenia, Inc. Dr. Kiener served as Chief Executive Officer and President of Zyngenia, Inc. and leads business and drug development efforts. Dr. Kiener served as Chief Scientific Officer of Ambrx, Inc. since August 2013. He served as an Executive Vice President of Research at MedImmune Inc. since February 2008 and its ...

Corporate Headquarters

805 King Farm Boulevard
Rockville, Maryland 20850

United States

Phone: 301-961-3400
Fax: 301-961-3440

Board Members Memberships



University of Oxford
Lancaster University

Other Affiliations

Annual Compensation

Total Annual Compensation$399,188

Stocks Options

All Other Compensation$7,699
Exercisable Options$75,000
Exercisable Options Value$672,000
Unexercisable Options$302,000
Unexercisable Options Value$2,206,190
Total Value of Options$2,878,190
Total Number of Options$377,000

Total Compensation

Total Annual Cash Compensation$674,072
Total Short Term Compensation$399,188
Other Long Term Compensation$7,699
Total Calculated Compensation$1,402,223

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


Michael W. Aguiar Chief Executive Officer, President, Director and Member of Stock Option Committee
Innoviva, Inc.
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science Committee
Progenics Pharmaceuticals, Inc.
Craig A. Wheeler Chief Executive Officer, President and Executive Director
Momenta Pharmaceuticals Inc.
A. J. Kazimi MBAFounder, Chairman, Chief Executive Officer and President
Cumberland Pharmaceuticals, Inc.
John Anthony Sedor Chairman, Chief Executive Officer and Member of Nominating Committee
Pernix Therapeutics Holdings, Inc.
Compensation as of Fiscal Year 2015.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sucampo Pharmaceuticals, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.